drugset / Trial / NCT03751488

A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients

NCT03751488

Phase 1 Completed 48 enrolled Luye Pharma Group Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will look at the Characteristics of LY03010 Versus INVEGA SUSTENNA® in the blood of Schizophrenia Patients

Timeline

Start
2018-12-12
Primary completion
2019-07-24
Completion
2019-07-24

Drugs

EvaluationDrugModalityDoseRoute
Subject LY03010 Unknown 117 mg
Subject LY03010 Unknown 156 mg
Subject LY03010 Unknown 351 mg
Comparator paliperidone palmitate Unknown 156 mg